Huang Guo, the Deputy Director of the State Administration for Market Regulation, conducted research on the development of radioactive drugs in Sichuan.

Recently, the member of the Party Group and Deputy Director of the National Medical Products Administration, Huang Guo, led a team to visit some of the radioactive drug research and production enterprises in Sichuan, as well as the National Key Laboratory of Biotherapy at Sichuan University, to conduct on-site inspections regarding radioactive drug research and development, quality management throughout the entire process, and regulatory scientific research. Huang Guo stated that the National Medical Products Administration attaches great importance to the specificity of radioactive drugs and strongly supports research and innovation in the field of radioactive drugs. It is necessary to focus on clinical needs, learn from international experiences, and establish a sound regulatory system and standards. It is important to keep pace with technological developments, actively respond to the development demands of enterprises, and research and establish an evaluation and approval system that fits the characteristics of the development of radioactive drugs. It is crucial to strictly control the quality, improve the quality management system of radioactive drugs, and promote the stable development of the industry.